Siemens Healthcare Diagnostics Gmbh

Dade Behring Inc.

Siemens Healthcare Gmbh

Siemens Healthcare Diagnostics Products Gmbh

Siemens Healthcare Diagnostics Holding Gmbh

William D Bedzyk

Tie Q Wei

Andreas Keller

Zhu Teng

Yi Feng Zheng

Herbert Schwarz

Manoj Sharma

Victor P Chu

Andreas Kappel

Cord Friedrich Stähler

Tatiana Mareeva

Steve P A Goss

Kelle M Garvey

Timothy J Gorzynski

Yuriy Smirnov

Nihmat Morjana

Ronald L Edwards

Sandra A Lewisch

Ronald A Edwards

Bogdan Draghici

Lynn M Schiavoni

Michaela Wicke

Tatiana Lebedeva

Heungyeung Yau

Allison Dominowski

Linda Marie Anderson-Mauser

Elsa Garcia

Ian Wright

Antibodies that specifically bind naloxone or naltrexone are disclosed. Also disclosed are conjugates used in the production of the antibodies, as well as methods of producing the antibodies. Also disclosed are methods of using the antibodies in direct assays for naloxone or naltrexone. Further disclosed are methods of reducing naloxone or naltrexone interference in opiate assays using the antibodies.

Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof

A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample.

Assay for analytes using multiple receptors

Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier. 

Binding partners specific for vitamin D epimers

The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.

Synthesis and application of procainamide analogs for use in an immunoassay

Growing community of inventors

Odessa, DE, United States of America

William D Bedzyk